HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen (DTG-Resist)
HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir-based 1st, 2nd or 3rd Line Regimens: the International Epidemiological Databases to Evaluate AIDS (IeDEA)
Sponsor: ETH Zurich
Listed as NCT06285110, this observational or N/A phase trial focuses on Hiv and remains completed. Sponsored by ETH Zurich, it has been updated 6 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2025 — Dec 2025 [monthly]
Recruiting
-
Apr 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
Mar 2024 — Jul 2024 [monthly]
Recruiting
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ETH Zurich
- University of Bern
- University of Bristol
- University of KwaZulu
- University of Zurich
For direct contact, visit the study record on ClinicalTrials.gov .